 Delcath Systems, Inc. DCTH, an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Companys Board of Directors has authorized a reverse stock split of the Companys common stock at a ratio of 1-for-100. The Companys Board of Directors was authorized to effect the reverse stock split by shareholder approval of its Proxy Solicitation filed with the Securities Exchange Commission on August 19, 2019. The proposal to effect a reverse stock split was approved by shareholders on September 17, 2019. 